Extending life span with a revolutionary approach
Working towards a crucial breakthrough in the way we treat disease: HAYA Therapeutics is revolutionising patient treatments by focusing on dark genome-derived RNAs, now recognised as regulatory genome RNAs. Thanks to its innovative approach, the company has attracted the attention of American pharmaceutical giant Eli Lilly. HAYA Therapeutics, which is supported by Innosuisse, is capitalising on this momentum to propel its technology to the forefront of the international scene and transform the treatment of certain diseases, while helping to increase life span.
Support from Innosuisse:
- Innovation project
- Start-up innovation project
- Start-up Coaching
- Innosuisse Certificate
